Arcturus治疗报告收入较低,股票下降,但分析师仍然乐观。 Arcturus Therapeutics reports lower earnings, stock drops, but analysts remain optimistic.

Arcturus治疗技术公司是一家开发MRNA药物的生物技术公司,它报告的季度人均收益低于预期(1.11美元),导致其库存下降到15.97美元。 Arcturus Therapeutics, a biotech firm developing mRNA medicines, reported a lower-than-expected quarterly earnings per share of ($1.11), leading its stock to drop to $15.97. 尽管收入下降,HC Wainwright和BTIG研究公司等分析家仍保持积极前景,设定目标价格达63美元。 Despite the earnings miss, analysts like HC Wainwright and BTIG Research maintain a positive outlook, setting target prices up to $63. 该公司专门从事罕见疾病的疫苗和治疗工作。 The company specializes in vaccines and treatments for rare diseases.